tailieunhanh - Safety and efficacy profle of Trastuzumab deruxtecan in solid cancer: Pooled reanalysis based on clinical trials

This study aimed to explore the efficiency and safety of the new generation antibody-drug conjugate Trastuzumab deruxtecan (DS-8201a) in treating HER2-positive solid cancers. By searching PubMed, Medline and Ovid for all clinical trials related to the safety and efficacy of DS-8201a. Event rates were calculated for all adverse events (AEs) to evaluate the safety of DS-8201a. Objective response rate (ORR) and progression-free survival (PFS) were summarized to assess the potency of DS-8201a. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN